Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM PeptideLibraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Two years of Covid-19Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Controlant Company InsightGo to article: ControlantGo to article: Contract Pharmaceuticals Limited CanadaGo to article: CommentGo to article: Ukraine: Russian invasion could cause spike in Covid-19 cases Go to article: First vaccines, now drugs: FDA’s second wave of emergency Covid-19 approvalsGo to article: International Women’s Day spotlight: endometriosisGo to article: Remote audits – stopgap measure or the new normal?Go to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: BaxterGo to article: In DepthGo to article: Two years of Covid-19: lessons the pandemic taught about delivering essential vaccinesGo to article: A perfect storm: Covid-19 viral vector manufacturing adds further burden to CAR-Go to article: Russia sanctions: what next for Sputnik Covid-19 vaccine production around the wGo to article: Profit for patients: can NFTs allow people to monetise their health data?Go to article: Navigating distribution challenges for rare disease drugsGo to article: NiproGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DataGo to article: North America is seeing a hiring boom in pharma digital media rolesGo to article: Filings buzz: 23% increase in industrial automation mentions in Q3 of 2021Go to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue